Small Caps – PharmAust appoints industry veteran to spearhead manufacturing ahead of critical MPL trial MediaBy Nickholas Bahr18/04/2024
Stockhead – PharmAust inks approval from Macquarie University for Open-Label MND extension study MediaBy Nickholas Bahr10/04/2024
Small Caps – PharmAust’s pioneering monepantel MND study receives HREC green light for final phase MediaBy Nickholas Bahr10/04/2024
The West – How PharmAust is offering hope to patients with MND and ALS using veterinary drug monepantel MediaBy Nickholas Bahr02/04/2024
Best Stocks – Revolutionizing ALS Treatment: New Findings Reveal Potential Game-Changer in Disease Management MediaBy Nickholas Bahr19/03/2024
Small Caps – PharmAust eyes FDA orphan drug designation for monepantel after positive MND/ALS trial results MediaBy Nickholas Bahr14/03/2024
Stockhead – PharmAust files groundbreaking MND/ALS clinical data with the FDA MediaBy Nickholas Bahr14/03/2024
ALS News Today – Vet drug monepantel slows ALS, MND disease progression in trial MediaBy Nickholas Bahr12/03/2024